Findings of a randomized phase III clinical trial demonstrate that a vaginally-applied topical gel containing the antimicrobicide tenofovir can prevent the transmission of herpes simplex virus type 2 (HSV-2), when used pericoitally. HSV-2 transmission was reduced from 21.0 to 10.2 cases per 100 person-years in women using this gel during unprotected sexual intercourse, significantly reducing the risk of genital ulcer disease in these women.
References
Abdool Karim, S. S. et al. Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N. Engl. J. Med. 373, 530–539 (2015)
Rights and permissions
About this article
Cite this article
Pericoital tenofovir gel reduces HSV-2 transmission. Nat Rev Urol 12, 537 (2015). https://doi.org/10.1038/nrurol.2015.217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.217